Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer

Yukinori Ozaki; Junji Tsurutani; Toru Mukohara; Tsutomu Iwasa; Masato Takahashi; Yuko Tanabe; Hidetaka Kawabata; Norikazu Masuda; Manabu Futamura; Hironobu Minami; Koji Matsumoto; Kenichi Yoshimura; Shigehisa Kitano; Toshimi Takano

doi:10.1016/j.dib.2022.108558

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer

Data Brief. 2022 Sep 1:45:108558. doi: 10.1016/j.dib.2022.108558. eCollection 2022 Dec.

Authors

Yukinori Ozaki^{1

2}, Junji Tsurutani³, Toru Mukohara⁴, Tsutomu Iwasa⁵, Masato Takahashi⁶, Yuko Tanabe¹, Hidetaka Kawabata⁷, Norikazu Masuda^{8

9}, Manabu Futamura¹⁰, Hironobu Minami¹¹, Koji Matsumoto¹², Kenichi Yoshimura¹³, Shigehisa Kitano^{14

15}, Toshimi Takano^{1

2}

Affiliations

¹ Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
² Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
³ Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
⁴ Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
⁵ Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan.
⁶ Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan.
⁷ Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan.
⁸ Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
⁹ Department of Breast and Endocrine Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
¹⁰ Breast Surgery, Gifu University Hospital, Gifu, Japan.
¹¹ Medical Oncology/Hematology, Internal Medicine, School of Medicine, Kobe University, Hyogo, Japan.
¹² Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan.
¹³ Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima University, Hiroshima, Japan.
¹⁴ Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
¹⁵ Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Abstract

The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues before treatment and blood samples at pretreatment, during and after treatment were collected. The serum samples were used to measure the concentrations of cytokines. Progression-free survival (PFS), overall survival (OS), and response were analyzed in association with the biomarker data using the Kaplan-Meier method and log-rank tests. Fifty patients were included in the biomarker analysis. Programmed death-ligand 1 (PD-L1) expression on tumor cells and immune cells were evaluated in tumor tissue samples using a Dako 28-8 immunohistochemistry assay and using a VENTANA SP142 immunohistochemistry assay. PD-L1 positive rates using anti-PD-L1 antibodies 28-8 (Combined positive score [CPS] ≥1) and SP142 (Immune cells [IC] ≥1) were 15% and 17%, respectively. The PFS and OS were not significantly different in the subgroups by PD-L1 expression. The median pretreatment vascular endothelial growth factor (VEGF)-A concentration was 116.1 pg/ml (range 0-740.23 pg/ml) on day 1 and decreased to <37 pg/ml on day 8 of cycle 1 in all patients. Subtypes (hormone receptor-positive HER2-negative or triple negative breast cancer), stage (recurrent or de novo stage IV) and liver metastasis (yes or no) were not significantly different between patients in VEGF-A high and VEGF-A low groups. PFS in the VEGF-A high group was similar to that in the VEGF-A low group.

Keywords: Bevacizumab; Immunotherapy; Metastatic breast cancer; Nivolumab; PD-L1; VEGF.